Achieving clinical outcomes with benralizumab in severe eosinophilic asthma patients in a real-world setting: ORBE II study
Abstract Background The ORBE II study aimed to describe the characteristics and clinical outcomes of adult patients with severe eosinophilic asthma (SEA) treated with benralizumab in a real-world setting in Spain. Methods ORBE II (NCT04648839) was an observational, retrospective cohort study in adul...
Main Authors: | Alicia Padilla-Galo, Isabel Moya Carmona, Pilar Ausín, Luis Carazo Fernández, Ismael García-Moguel, José Luis Velasco-Garrido, Rubén Andújar-Espinosa, Francisco Casas-Maldonado, Eva Martínez-Moragón, Carlos Martínez Rivera, Elisabet Vera Solsona, Fernando Sánchez-Toril López, Andrea Trisán Alonso, Marina Blanco Aparicio, Marcela Valverde-Monge, Borja Valencia Azcona, Marta Palop Cervera, Javier Nuevo, Jesús Sánchez Tena, Gustavo Resler, Elisa Luzón, Alberto Levy Naon |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-09-01
|
Series: | Respiratory Research |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12931-023-02539-7 |
Similar Items
-
Real-world study in severe eosinophilic asthma patients refractory to anti-IL5 biological agents treated with benralizumab in Spain (ORBE study)
by: Eva Martínez-Moragón, et al.
Published: (2021-12-01) -
Real-life experience with benralizumab during 6 months
by: A. Padilla-Galo, et al.
Published: (2020-06-01) -
Real-life cost-effectiveness of benralizumab in patients with severe asthma
by: A. Padilla-Galo, et al.
Published: (2021-05-01) -
A Phylogenetic Study of the Concept of Celestial Orb
by: Mohammad Mahdi Sadrforati, et al.
Published: (2022-12-01) -
New horizons for the treatment of severe, eosinophilic asthma: benralizumab, a novel precision biologic
by: Caminati M, et al.
Published: (2019-05-01)